Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Sang Mi | - |
dc.contributor.author | Choi, Seong Ji | - |
dc.contributor.author | Kim, Min Jung | - |
dc.contributor.author | Choi, Jung Yoon | - |
dc.contributor.author | Kim, Hong Jun | - |
dc.contributor.author | Lee, Suk-Young | - |
dc.contributor.author | Kang, Eun Joo | - |
dc.date.accessioned | 2021-09-03T22:25:51Z | - |
dc.date.available | 2021-09-03T22:25:51Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 1792-1074 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88213 | - |
dc.description.abstract | Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with poor prognosis. Surgery is the treatment of choice, but numerous cases are inoperable. For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | PHASE-III | - |
dc.subject | SURVIVAL | - |
dc.subject | ASBESTOS | - |
dc.title | Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.identifier.doi | 10.3892/ol.2016.4598 | - |
dc.identifier.scopusid | 2-s2.0-84973487281 | - |
dc.identifier.wosid | 000379960200037 | - |
dc.identifier.bibliographicCitation | ONCOLOGY LETTERS, v.12, no.1, pp.213 - 216 | - |
dc.relation.isPartOf | ONCOLOGY LETTERS | - |
dc.citation.title | ONCOLOGY LETTERS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 213 | - |
dc.citation.endPage | 216 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ASBESTOS | - |
dc.subject.keywordAuthor | malignant mesothelioma | - |
dc.subject.keywordAuthor | pericardium | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | pemetrexed | - |
dc.subject.keywordAuthor | cisplatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.